Thursday, September 3, 2015

Glaxo's R&D shuffle means the end of red wine unit (Sirtris Pharmaceuticals)

GlaxoSmithKline's announcement of reshuffling of its research and development people and facilities impacted employees at facilities in Philadelphia suburbs of Upper Merion and Upper Providence, but it also involved the closing of its red wine unit in Cambridge, Mass.

Glaxo's R&D shuffle means the end of red wine unit (Sirtris Pharmaceuticals)

0 comments

 GlaxoSmithKline's announcement of reshuffling of its research and development people and facilities impacted employees at facilities in Philadelphia suburbs of Upper Merion and Upper Providence, but it also involved the closing of its red wine unit in Cambridge, Mass.

Red wine?

Sirtris Pharmaceuticals is the biotech company that Glaxo bought in 2008 for $720 million. But Glaxo said it would close that unit and move some - but not all - of the 60 employees to Upper Providence.

Sirtris researchers and folks from Harvard published a paper in Science magazine in the last week suggesting that a compound in red wine (and along with a lot of elements) could extend the life span of small laboratory organisms.

The Inquirer's Tom Avril wrote about the paper earlier this week and a link is here.

Glaxo spokeswoman Melinda Stubbee said the unit "has been a success and needs to move to the next level," and would benefit from the collected "resources and expertise" that will be available in the new mix in Upper Providence.

A link to Wednesday's Inquirer story on Philadelphia shifting is here.

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell
Also on Philly.com:
letter icon Newsletter